Il Mondo Maggioli

Le nostre attività integrate affiancano la Pubblica Amministrazione Locale e Centrale, i Liberi Professionisti e le Aziende nel semplificare i processi e migliorare i servizi
Soluzioni e ServiziTecnologia e conoscenza sono da sempre le nostre passioni, il nostro business e il modo con cui siamo sempre riusciti a rispondere alle richieste di un mercato in continua evoluzione
Back

AI / XAI / Data / Cloud

INCISIVE

A Multimodal AI-based Toolbox and an Interoperable Health Imaging Repository for the Empowerment of Imaging Analysis related to the Diagnosis, Prediction and Follow-up of Cancer

Call: H2020-SC1-DT-TDS-05-2020

Ref: Grant Agreement No. 952179

Duration: Oct 2020 – Mar 2024 (42 months)

Budget: € 9.995.727,50

Financing: € 9.995.727,50

Funds: € 702.500,00

Role: Project Coordinator, System Integrator, Technological Provider

Website: https://incisive-project.eu/

LinkedIn: https://www.linkedin.com/groups/9022935/

Twitter: https://twitter.com/IncisiveEu

Description

INCISIVE aims to address three major open challenges in order to explore the full potential of AI solutions in cancer imaging: (1) AI challenges unique to medical imaging, (2) Image labelling and annotation and (3) Data availability and sharing. In order to do that INCISIVE plans to develop and validate: (1) an AI-based toolbox that enhances the accuracy, specificity, sensitivity, interpretability and cost-effectiveness of existing cancer imaging methods, (2) an automated-ML based annotation mechanism to rapidly produce training data for machine learning research and (3) a pan-European repository federated repository of medical images, that will enable the secure donation and sharing of data in compliance with ethical, legal and privacy demands, increasing accessibility to datasets and enabling experimentation of AI-based solutions.

The INCISIVE models and analytics will utilize various cancer imaging scans, biological data and EHRs, and will be trained with 1 PB of available data provided by 8 partners within the project. INCISIVE solution will be investigated in four validation studies for Lung, Breast, Prostate and Colorectal Cancer, taking place in 8 sites, from 5 countries (Cyprus, Greece, Italy, Serbia and Spain), with participation of at least 2000 patients and a total duration of 1.5 year. 

Partner

  • Maggioli S.p.A. (Italy)
  • Centro Regionale ICT SCRL (Italy)
  • Institute of Communication and Computer Systems (Greece)
  • Centre for Research and Technology Hellas (Greece)
  • Barcelona Supercomputing Centre (Spain)
  • European Dynamics SA (Luxembourg)
  • Telesto IoT Solutions Ltd. (United Kingdom)
  • Squaredev BV (Belgium)
  • Visaris D.o.o (Serbia)
  • Università degli Studi di Napoli Federico II (Italy)
  • Aristotle University of Thessaloniki (Greece)
  • Cipro University of Technology (Cyprus)
  • Kingston University (United Kingdom)
  • Hellenic Cancer Society (Greece)
  • Cipro Association of Cancer Patients and Friends (Cyrpus)
  • Università degli Studi di Roma Tor Vergata (Italy)
  • University of Athens (Greece)
  • University of Helsinki (Finland)
  • University of Novi Sad (Serbia)
  • German Oncology Centre (Cyprus)
  • Biomedical Research Institute August Sunyer (Spain)
  • Foundation Tic Salut (Spain)
  • Time.Lex (Belgium)
  • White Research SPRL (Belgium)
  • Medtronic SA (Spain)
  • Adapt IT GmbH (Germany)